All In Biotech

NDA 017522 · Bausch

Retin-A

Tretinoin · Topical · Retinoid

Last checked: Nov 20, 2026Latest source record: May 13, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1974

Jul 19, 1974

Approved uses

1

Original approval plus efficacy supplements

Registered trials

375

82 Phase 3, 25 recruiting

FAERS reports

7,870

4,782 serious, 883 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 11, 2025.

INDICATIONS AND USAGE Tretinoin is indicated for topical application in the treatment of acne vulgaris. The safety and efficacy of the long-term use of this product in the treatment of other disorders have not been established.

Therapeutic areas: Ophthalmology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 19, 1974 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
  • RETIN-A · TRETINOIN 0.05% · CREAM, TOPICAL · Prescription · TE AB1

Clinical trials

Interventional ClinicalTrials.gov studies with "Tretinoin" as an intervention, any sponsor and status, largest first.

All 375 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use965
  • drug ineffective813
  • pain586
  • product use in unapproved indication509
  • vomiting504
  • nausea442
  • rash434
  • headache426
  • diarrhoea411
  • paraesthesia397
  • abdominal pain upper387
  • fatigue371

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200448
200548
200638
200752
2008135
200999
2010112
2011159
2012203
2013118
2014178
2015318
2016528
2017478
2018533
2019455
2020445
2021453
2022576
2023646
2024758
2025887
2026603

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Retin-A (Tretinoin)

2024 spending

$1.0M

Beneficiaries

14,882

32,166 claims

Per beneficiary

$68

$1.02 per unit

View as table
YearSpending
2020$1,237,353
2021$1,447,315
2022$1,631,170
2023$1,186,086
2024$1,005,782

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 422 on PubMed

Sponsor: Bausch

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.